Literature DB >> 18278073

Rituximab as salvage therapy for refractory chronic GVHD.

M Mohty, N Marchetti, J El-Cheikh, C Faucher, S Fürst, D Blaise.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18278073     DOI： 10.1038/bmt.2008.12

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  20 in total

1.  Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.

Authors:  Zoya Kuzmina; Verena Gounden; Lauren Curtis; Daniele Avila; Tiffani Taylor Rnp; Judy Baruffaldi; Edward W Cowen; Haley B Naik; Sarfaraz A Hasni; Jacqueline W Mays; Sandra Mitchell; Kristin Baird; Seth M Steinberg; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

2.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

3.  Autoimmune-like hepatitis after allogeneic hematopoietic stem cell transplantation: humoral hepatic GvHD.

Authors:  D Koyama; M Ito; E Yokohata; K Watakabe; K Onodera; T Goto; A Seto; K Watanabe; M Doisaki; Y Ozawa; T Yamaguchi; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2016-08-15       Impact factor: 5.483

4.  Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.

Authors:  Cesar Homero Gutiérrez-Aguirre; Olga Graciela Cantú-Rodríguez; Omar David Borjas-Almaguer; Oscar González-Llano; José Carlos Jaime-Pérez; Manuel Solano-Genesta; Miguel Gómez-Guijosa; Consuelo Mancias-Guerra; Luz Tarin; David Gómez-Almaguer
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

5.  B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.

Authors:  Jessica L Allen; Matthew S Fore; Jenna Wooten; Philip A Roehrs; Nazmim S Bhuiya; Todd Hoffert; Andrew Sharf; Allison M Deal; Paul Armistead; James Coghill; Don A Gabriel; Robert Irons; Amber Essenmacher; Thomas C Shea; Kristy Richards; Corey Cutler; Jerome Ritz; Jonathan Serody; Albert S Baldwin; Stefanie Sarantopoulos
Journal:  Blood       Date:  2012-08-14       Impact factor: 22.113

6.  Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

Authors:  Jennifer A Kanakry; Christopher D Gocke; Javier Bolaños-Meade; Douglas E Gladstone; Lode J Swinnen; Amanda L Blackford; Ephraim J Fuchs; Carol Ann Huff; Ivan Borrello; William H Matsui; Robert A Brodsky; Gary L Rosner; Satish Shanbhag; Leo Luznik; Richard J Jones; Richard F Ambinder; Yvette L Kasamon
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

Review 7.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

8.  Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation.

Authors:  Persis P Wadia; Marc Coram; Randall J Armstrong; Michael Mindrinos; Atul J Butte; David B Miklos
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

9.  Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

Authors:  Corey Cutler; Haesook T Kim; Bhavjot Bindra; Stefanie Sarantopoulos; Vincent T Ho; Yi-Bin Chen; Jacalyn Rosenblatt; Sean McDonough; Phandee Watanaboonyongcharoen; Philippe Armand; John Koreth; Brett Glotzbecker; Edwin Alyea; Bruce R Blazar; Robert J Soiffer; Jerome Ritz; Joseph H Antin
Journal:  Blood       Date:  2013-07-16       Impact factor: 22.113

10.  Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.

Authors:  Marieke Griffioen; Esther H M van Egmond; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.